SIGA Technologies, Inc.

SIGA Technologies, Inc.

SIGA Technologies, Inc.

Overview
Date Founded

1995

Headquarters

660 Madison Avenue, Suite 1700, New York, New York, 10065

Type of Company

Public

Employees (Worldwide)

42

Industries

Pharmaceuticals
Biotechnology

Company Description

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Contact Data
Trying to get in touch with decision makers at SIGA Technologies, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Executive Vice President & Chief Financial Officer

General Counsel & Chief Administrative Officer

Chief Scientific Officer & Executive Vice President

Owner

Chief Administrative Officer & General Counsel

Chief Information Officer

Director

Senior Vice President-Operations & Chief Supply Chain Officer

Accounting Manager

Board of Directors

Director-Eastern Regional Medical Center at Cancer Treatment Centers of America, Inc.

Founder & Managing Member at Woodbury Hill Partners

Former Chief Scientific Officer & Senior Vice President at Sanofi

Former Vice President, General Counsel & Compliance Officer, North America & Corporate Functions at Avon Products, Inc.

Senior Vice President, Chief Financial Officer & Corporate Secretary at CenterState Holding Co.

Chief Executive Officer at SIGA Technologies, Inc.

Former Associate at Union Capital Associates LP

Independent Director at SIGA Technologies, Inc.

Paths to SIGA Technologies, Inc.
Potential Connections via
Relationship Science
You
SIGA Technologies, Inc.
Owners & Shareholders
Details Hidden

Esopus Creek Management is a small-cap investor that focuses primarily on investments in the US retail and consumer durables sectors. The firm often engages in shareholder activism

Details Hidden

MFP Investors seeks to generate high long-term total return through opportunistic investing and the use of a disciplined value investment approach. Their approach emphasizes investments in common stock, preferred stock and corporate debt securities which are available at prices MFP believes are less than their intrinsic value. The firm''s recommendations are based on analysis and original research which take into account, among other factors, the relationship of book value to market value of the securities, cashflow, and multiples of earnings of comparable securities and industry characteristics. The firm may also use various other techniques including, short selling, hedging, risk arbitrage and bankruptcy investing. They may invest in a variety of securities including U.S. and non-U.S. securities; equity securities, debt securities of any credit quality or seniority including defaulted debt securities or junk bonds; preferred stock; securities of companies involved in mergers, consolidations or liquidations; restricted securities; other evidences of equity ownership; smaller capitalized companies; interests in limited partnerships or limited liability companies; and any securities convertible into or exercisable for any of the foregoing; options; warrants; and private placements.

Details Hidden

AltraVue Capital is a long-term, value-focused investor that consistently applies a rigorous and differentiated investment process. The investment objective of the firm’s fund is to generate attractive long-term, risk adjusted returns that exceed market rates of return for publicly-traded equity securities. The Fund is a highly-concentrated, long-only, value-oriented equity strategy. It principally makes long-term investments in a global portfolio of 10-20 attractively priced (in their view) businesses with identifiable opportunities to grow intrinsic value.

Recent Transactions
Details Hidden

SIGA Technologies, Inc. issued USD Common Stock

Transaction Advisors
Accountant

Advised onSIGA Technologies, Inc. purchases Plexus Vaccine, Inc.

Escrow Agent

Advised onSIGA Technologies, Inc. issued USD Common Stock

Selling Group Member

Advised onSIGA Technologies, Inc. issued USD Common Stock

Advisors & Consultants
Advisor

KCSA Strategic Communications provides public relations services. It offers Investor Relations, Public Relations, Naming & Corporate Identity, Web Design & Development, Online Marketing, Media Planning, Advertising and Social Media services. The company was founded in 1969 and is headquartered in New York, NY.

Legal Advisor

Counsel at Clifford Chance LLP

Legal Advisor

Of Counsel at Paul, Weiss, Rifkind, Wharton & Garrison LLP

Legal Advisor

Member (Attorney) at Cole Schotz P.C.

Clients

The federal government of Canada is the body responsible for the federal administration of Canada. In Canadian English, the term can mean either the collective set of institutions (the legislative, executive, and judicial branches) or specifically the Queen-in-Council (the executive, also called Her Majesty's Government.

The Government of the United States of America is the federal government of the republic of fifty states that constitute the United States, as well as one capital district, and several other territories. The federal government is composed of three distinct branches: legislative, executive and judicial, whose powers are vested by the U.S. Constitution in the Congress, the President, and the federal courts, including the Supreme Court, respectively.

Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada.

Key Stats and Financials As of 2020
Market Capitalization
$506M
Total Enterprise Value
$462M
Earnings Per Share
$0.71
Revenue
$125M
EBITDAMargin
68.05%
Enterprise Value / Sales
3.7x
Net Profit
$56.3M
Total Equity
$130M
Total Debt
$2.35M
EBITDA
$85M
Enterprise Value EBITDAOperating
5.41x
Debt TEV
0.01x
TEVNet Income
8.2x
Three Year Compounded Annual Growth Rate Of Revenue
116.76%
Non-Profit Donations & Grants
$2,500 - $4,999
2015
$2,500 - $4,999
2014
Suppliers
Catalent, Inc. Other Business & Consulting Services | Somerset, NJ

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets, and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy; formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges; and analytical development and testing services for large molecules. The Oral and Speciality Delivery segment consists of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment involves packaging, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Powdersize, Inc. Wholesale: Consumer Non-Durables/Sundries | Quakertown, PA

Powdersize, Inc. provides contract dry powder sizing services to the pharmaceutical, food, and cosmetic industries. It offers jet, pin, hammer, and high potency milling; pneumatic, vibratory, and air swept screening; and analytical testing. The company was founded in 1993 and is headquartered in Quakertown, PA.

Albemarle Corp. Chemicals | Charlotte, NC

Albemarle Corp. engages in developing, manufacturing, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Lithium, Bromine Specialties, and Catalysts. The Lithium segment engages in developing and manufacture of basic lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and value-added lithium specialties and reagents. The Bromine Specialties segment consists of bromine and bromine-based business includes products used in fire safety solutions and other specialty chemicals applications. The Catalysts segment contain two product lines: clean fuels technologies, which is primarily composed of hydro processing catalysts, and heavy oil upgrading that comprises of fluidized catalytic cracking catalysts and additives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Competitors
Emergent BioSolutions, Inc. Pharmaceuticals - Rockville, Maryland

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Bavarian Nordic A/S Biotechnology - Kvistgaard, Denmark

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Chimerix, Inc. Pharmaceuticals - Durham, North Carolina

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. Based on proprietary lipid conjugate technology, the company's two clinical stage compounds have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. CMX001 is a Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate. Its broad spectrum activity against double-stranded DNA (dsDNA) viruses without the myelotoxicity and nephrotoxicity of current agents has the potential to improve outcomes for immunosuppressed patients. Chimerix's second clinical-stage antiviral compound, CMX157 is a Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent tenofovir-diphosphate. It has the potential to directly address several limitations of current HIV and HBV therapies. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, influenza, malaria and other global public health needs.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by SIGA Technologies, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of SIGA Technologies, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and SIGA Technologies, Inc..